BioSpace News Archive

Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection and comparison with leading glaucoma treatments Preclinical studies of CBDVHS will examine its utility for ocular, neurological, pain and addiction disorders San Diego, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a prec

Invetx, a pioneer in protein-based therapeutics for animal health, announced today that it has raised an additional $10.25 million in its Series A financing, bringing the total amount to $25.5 million. New investors include Cas

FEND Administration Lowered Exhaled Particles in Subjects Including Healthy Subjects and a COVID-19 Patient Partner Sensory Cloud to Distribute FEND Worldwide, with Pulmatrix Receiving Escalating Royalties upon Commencement of Sales [30-September-2020] LEXINGTON, Mass. , Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage bioph

Thrive Earlier Detection Corp., a company dedicated to incorporating earlier cancer detection into routine medical care, today announced it has strengthened its leadership team with key appointments. Sam Asgarian, M.D., has been appointed to chief medical officer and Frank Diehl, Ph.D., as executive vice president of product solutions. Dina Ciarimboli, f

Reven Selects eClinical Services Provider DSG for Clinical Data Management Services to Accelerate the Clinical Development of Reven’s Investigational Drug Product RJX as a Treatment Against COVID-19 GOLDEN, Colo.--( BUSINESS WIRE )-- Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19

Today as the 6th annual “Limb Girdle Muscular Dystrophy Awareness Day” is celebrated worldwide, LGMD Awareness Foundation, Inc. is proud to announce their formation as a 501(c)(3) non-profit advocacy organization dedicated to globally raising awareness of the rare neuromuscular diseases known as Limb Girdle Muscular Dystrophy (LGMD).

Highlights : Murdoch Children’s Research Institute to evaluate the in-vivo antimicrobial activity of RECCE ® 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies program Studies led by H. pylori infectious disease expert Professor Philip Sutton Multiple world-first data opportunities over 12 months study program – anticipated human clinical trial beyond SYDNEY, Australia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Recce Pharma

Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today the dosing of the first patient in two separate Phase II clinical trials of Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), in mainland China.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the Northeast Amyotrophic Lateral Sclerosis (NEALS) 19 th Annual Meeting, being held virtually Sept. 30 – Oct. 1, 2020 . The data provide deeper insight into U.S. experience wit

MDA continues to step up fight against ALS during this challenging time, building on its $168 million research commitment